Abstract
Maintenance of medically induced remission is a clinical challenge in Crohn’s disease (CD), since it is a chronic disease and that often occurs in young people. The introduction of immunosuppressors and biologics has significantly improved the management of these patients, however efficacy and safety of these treatments in the very long term still needs clarification. Furthermore, scientific research is driven more into new drugs to induce remission rather then maintenance.
Keywords: Crohn's disease, maintenance of remission, meta-analysis, Randomized Controlled Trials
Reviews on Recent Clinical Trials
Title:Randomized Controlled Trials in Maintenance of Remission in Crohn’s Disease
Volume: 7 Issue: 4
Author(s): Renata D’Inca and Roberta Caccaro
Affiliation:
Keywords: Crohn's disease, maintenance of remission, meta-analysis, Randomized Controlled Trials
Abstract: Maintenance of medically induced remission is a clinical challenge in Crohn’s disease (CD), since it is a chronic disease and that often occurs in young people. The introduction of immunosuppressors and biologics has significantly improved the management of these patients, however efficacy and safety of these treatments in the very long term still needs clarification. Furthermore, scientific research is driven more into new drugs to induce remission rather then maintenance.
Export Options
About this article
Cite this article as:
D’Inca Renata and Caccaro Roberta, Randomized Controlled Trials in Maintenance of Remission in Crohn’s Disease, Reviews on Recent Clinical Trials 2012; 7 (4) . https://dx.doi.org/10.2174/1574887111207040270
DOI https://dx.doi.org/10.2174/1574887111207040270 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sepsis-induced Cardiomyopathy
Current Cardiology Reviews Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Combined Transcriptomic and Proteomic Analyses of Cerebral Frontal Lobe Tissue Identified RNA Metabolism Dysregulation as One Potential Pathogenic Mechanism in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Current Neurovascular Research Adult-Onset Genetic Leukoencephalopathies. Focus on the More Recently Defined Forms
Current Molecular Medicine Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Imaging Markers of Neurologic Damage in COVID-19: A Systematic Review
Current Medicinal Chemistry The Importance of NAD in Multiple Sclerosis
Current Pharmaceutical Design Individualized Treatment Planning in Oncology: Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance
Current Pharmaceutical Design Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Acute Ischemic Cerebrovascular Events on Antiplatelet Therapy: What is the Optimal Prevention Strategy?
Current Pharmaceutical Design Cyclosporin and Organ Specific Toxicity: Clinical Aspects, Pharmacogenetics and Perspectives
Current Clinical Pharmacology HELLP Syndrome: Pathophysiology and Current Therapies
Current Pharmaceutical Biotechnology Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action
CNS & Neurological Disorders - Drug Targets Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer
Current Pharmaceutical Design Design, Sar, and Metabolism Study of Crucifereae Family Compound (Spirobrassinin) and its Analogs for Antiangiogenic Potential Targeting Hsp90
Current Proteomics Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry